Download PDF
Thromb Haemost 1994; 71(05): 663-669
DOI: 10.1055/s-0038-1642500
Review Article
Schattauer GmbH Stuttgart

Aprotinin Could Promote Arterial Thrombosis in Pigs: a Prospective Randomized, Blind Study

Ch M Samama
1   The Département d’Anesthésie, Hôpital Pitié, Paris, France
,
E Mazoyer
2   INSERM U 353, Institut des Vaisseaux et du Sang, Paris, France
,
P Bruneval
3   Département d’Anatomo-Pathologie, Hôpital Broussais, Paris, France
,
P Ciostek
2   INSERM U 353, Institut des Vaisseaux et du Sang, Paris, France
,
Ph Bonnin
4   Laboratoire d’Explorations fonctionnelles, Hôpital Lariboisière, Paris, France
,
M Bonneau
5   N.N.R.A, Jouy-en-Josas, France
,
J Roussi
2   INSERM U 353, Institut des Vaisseaux et du Sang, Paris, France
,
O Bailliart
4   Laboratoire d’Explorations fonctionnelles, Hôpital Lariboisière, Paris, France
,
G Pignaud
2   INSERM U 353, Institut des Vaisseaux et du Sang, Paris, France
,
P Viars
1   The Département d’Anesthésie, Hôpital Pitié, Paris, France
,
J P Caen
2   INSERM U 353, Institut des Vaisseaux et du Sang, Paris, France
,
L O Drouet
2   INSERM U 353, Institut des Vaisseaux et du Sang, Paris, France
› Author Affiliations
Further Information

Publication History

Received 07 September 1992

Accepted after revision 17 January 1994

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Haemostatic properties of aprotinin could be associated with an increased risk of thrombosis. A randomized, blinded study was conducted to consider the potential thrombogenicity of aprotinin, using the Fobs’ model on femoral arteries in 12 pigs. The flow variations were measured by a pulsed Doppler in anaesthetised animals. Ear immersion bleeding time was performed. During the first part of the study, a stenosis was performed successively on both femoral arteries, each for a period of 30 min, without prior injury, to assess the integrity of the vessel, and to check that the arteries did not develop cyclic flow reductions (CFR), permanent cessation of flow (PCF) or partial thrombosis, when a stenosis is applied. Then the clamp was released and a bolus of placebo (saline), or aprotinin (4 millions KIU, followed by a continuous infusion of 1 million KIU · h−1), was administered. At the end of the bolus, the second part of the study began. Stenosis was applied to the arteries. If CRF, PCF, or partial thrombosis were observed without prior injury then the infused drug (aprotinin or saline) was considered a prothrombotic drug, and the opposite artery was studied. For each animal, right and left femoral artery segments were fixed and studied (morphologic study). Eighteen arteries were studied. In the aprotinin group, 6 arteries out of 8 developed an unexpected thrombosis, as compared with only 2 out of 10 arteries in the control group (p = 0.02). The morphologic study confirmed the occurrence of thrombosis in 4 out of 7 arteries in the aprotinin group, as compared with only 1 out of 9 in the control group. The ear immersion bleeding time was not different in either group. No difference could be demonstrated with regard to the values of activated partial thromboplastin time, prothrombin time and fibrinogen.

Aprotinin may have promoted the development of thrombosis in the pig.

 

  • References

  • 1 Grant FC. Autotransfusion. Ann Surg 1981; 74: 253-4
    PubMedGoogle Scholar
  • 2 Anderson BB, Tomasulo PA. Current autologous transfusion practices. Transfusion 1988; 28: 394-6
    CrossrefPubMedGoogle Scholar
  • 3 Surgenor D. The patients blood is the safest blood. N Engl J Med 1987; 321: 542-4
    PubMedGoogle Scholar
  • 4 Salzman EW, Weinstein MJ, Weintraub RM, Ware JA, Thurer RL, Robertson L, Donovan A, Gaffney T, Bertele V, Troll J, Smith M, Chute LE. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. N Engl J Med 1986; 314: 1402-6
    CrossrefPubMedGoogle Scholar
  • 5 Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneim-Forsch Drug Res 1983; 33: 479-94
    PubMedGoogle Scholar
  • 6 Kunitz M, Northrop JH. Isolation from beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor and an inhibitor trysin compound. J Gen Physiol 1936; 19: 991-1007
    CrossrefPubMedGoogle Scholar
  • 7 Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusions after repeat open heart surgery. Lancet 1987; ii: 1289-91
    PubMedGoogle Scholar
  • 8 Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm W, Barankay A, Sebening A, Richter JA. Influence of high-dose aprotinin treatment on blood and coagulation pattern in patients undergoing myocardial revascu larization. Anesthesiology 1990; 73: 1119-26
    CrossrefPubMedGoogle Scholar
  • 9 Lu H, Soria C, Commin P, Soria J, Piwnica A, Schumann F, Régnier O, Legrand Y, Caen JP. Haemostasis in patients undergoing extracorporeal circulation: the effect of Aprotinin (Trasylol). Thromb Haemost 1991; 66: 633-7
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Marx G, Pokar H, Reuter H, Doering V, Tilsner V. The effects of Aprotinin on haemostatic function during cardiac surgery. J Cardiothorax Vasc Anesth 1991; 5: 467-74
    PubMedGoogle Scholar
  • 11 Neuhaus P, Bechstein WO, Lefebre B, Blumhardt G, Slama K. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet 1989; ii: 924-5
    PubMedGoogle Scholar
  • 12 Godet G, Bertrand G, Fleron MH, Barré E, Baron JF, Coriat P, Kieffer E, Viars P. Aprotinin decreases pedopeialive bleeding and blood product requirement during thoracic aortic surgery performed with extraeorporeal circulation. Anesthesiology 1992; 77: A265 (abstract)
    CrossrefPubMedGoogle Scholar
  • 13 Thomson JF, Roath OS, Francis JL, Webster JHH, Chant ADB. Aprotinin in peripheral vascular surgery. Lancet 1990; 336: 911
    CrossrefPubMedGoogle Scholar
  • 14 Youngberg JA. Aprotinin and thrombus formation on pulmonary artery catheters: a piece of the coagulation puzzle. J Cardiothorac Anesth 1990; 4: 155-8
    CrossrefPubMedGoogle Scholar
  • 15 Mertz ET. The anomaly of a normal Duke’s and very prolonged bleeding time in swine suffering from an inherited bleeding disease. Am J Physiol 1942; 136: 360-2
    PubMedGoogle Scholar
  • 16 Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-70
    CrossrefPubMedGoogle Scholar
  • 17 Folts JD, Gallagher K, Rowe GG. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation?. Circulation 1982; 65: 248-55
    CrossrefPubMedGoogle Scholar
  • 18 Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPII/IIIa receptors. Circulation 1989; 80: 1766-74
    CrossrefPubMedGoogle Scholar
  • 19 Nichols TC, Bellinger DA, Johnson TA, Lamb MA, Griggs TR. Von Willebrand’s disease prevents occlusive thrombosis in stenosed and injured porcine coronary arteries. Circ Res 1986; 59: 15-26
    CrossrefPubMedGoogle Scholar
  • 20 Samama ChM, Bonneau M, Bailliart O, Pignaud G, Scrobohaci ML, Caen JP, Viars P, Drouet L. Absence of side effects of Hydroxyethylstarch 200 in a porcine model of experimental arterial thrombosis. Thromb Res 1991; 65: 691-8
    PubMedGoogle Scholar
  • 21 Samama ChM, Bonnin P, Bonneau M, Pignaud G, Mazoyer E, Bailliart O, Maffrand JP, Viars P, Caen JP, Drouet L. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thromb Haemost 1992; 68: 500-5
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Royston D. The serine antiprotease aprotinin (Trasylol): a novel approach to reducing postoperative bleeding. Blood Coag Fibrinol 1990; 1: 55-69
    CrossrefPubMedGoogle Scholar
  • 23 Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L. Wildevuur CRH. Aprotinin protects platelets against the initial effects of cardiopulmonary bypass. J Thor Cardiovasc Surg 1990; 99: 788-97
    PubMedGoogle Scholar
  • 24 Cramer EM, Lu H, Caen J, Soria C, Berndt MC, Tenza D. Differential redistribution of platelet glycoprotein lb and Ilb/IIIa after plasmin stimulation. Blood 1991; 77: 694-99
    PubMedGoogle Scholar
  • 25 Edmunds LH, Niewiarowski S, Colman RW. Invited letter concerning Aprotinin. J Thor Cardiovasc Surg 1991; 101: 1103-4
    PubMedGoogle Scholar
  • 26 Laurel MT, Ratnoff OD, Everson B. Inhibition of the activation of Hageman factor (factor XII) by aprotinin (Trasylol). J Lab Clin Med 1992; 119: 580-5
    PubMedGoogle Scholar
  • 27 Dietrich W, Spannagl M, Jochum M, Wendt P, Barankay A, Richter JA. Investigations on the mechanisms of action of aprotinin in cardiac surgery. In: Blood Use in Cardiac Surgery. Friedei N, Hetzer R, Royston D. (eds) Springer Verlag; New York, NY: 1991: 232-9
    Google Scholar
  • 28 Espana F, Estelles A, Griffin JH, Aznar J, Gilabert J. Aprotinin (trasylol) is a competitive inhibitor of activated protein C. Thromb Res 1989; 56: 751-6
    CrossrefPubMedGoogle Scholar
  • 29 De Haan J, Van Oeveren W. Pharmacology of aprotinin, an haemostatic preservative. In: Hemostasis and thrombosis in cardiovascular surgery. Samama ChM. ed Arnette-Blackwell; Paris, France: 1993: 69-77
    Google Scholar
  • 30 Naeye L. Thrombotic state after haemorrhagic diathesis, a possible complication of therapy with epsilon amino-caproic acid. Blood 1962; 19: 694-701
    PubMedGoogle Scholar
  • 31 Davis D, Howell DA. Tranexamic acid and arterial thrombosis. Lancet 1977; i: 49
    PubMedGoogle Scholar
  • 32 Bohrer H, Fleisher F, Lang J, Vahl C. Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high dose aprotinin. J Cardiothorac Anesth 1990; 4: 222-5
    CrossrefPubMedGoogle Scholar
  • 33 Cosgrove DM, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LAR, Stewart RW, Mac Carthy PM, Loop FD. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-8
    CrossrefPubMedGoogle Scholar
  • 34 Sundt TM, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993; 55: 1418-24
    CrossrefPubMedGoogle Scholar
  • 35 Lequeau F, Bourgain JL, Castaigne D, Samama ChM. Use of aprotinin during cyto-reductive surgery of ovarian cancer. Br J Anaesth 1993; 70 S (Suppl. 01) 50 (abstract)
    CrossrefPubMedGoogle Scholar
  • 36 Quereshi A, Lamont J, Burke P, Grace P, Bouchier-Hayes D. Aprotinin: the ideal anticoagulant?. Eur J Vasc Surg 1992; 6: 317-20
    CrossrefPubMedGoogle Scholar